Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;12(5):37-45.
doi: 10.17691/stm2020.12.5.04. Epub 2020 Oct 28.

Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

S V Krasilnikova  1 , E V Tush  2 , P A Frolov  3 , D Yu Ovsyannikov  4 , A B Terentyeva  5 , N I Kubysheva  6 , T I Eliseeva  7
Affiliations

Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

S V Krasilnikova et al. Sovrem Tekhnologii Med. 2021.

Abstract

The involvement of periostin in Th2-dependent allergic inflammation has been documented. However, the significance of periostin as a biomarker of local allergic inflammation in the nasal mucosa (NM) of patients with atopic bronchial asthma (BA) and allergic rhinitis (AR) is yet to be determined. The aim of the study was to determine the presence of periostin and evaluate its role as a non-invasive marker of allergic inflammation in the nasal secretions of children with atopic BA and AR.

Materials and methods: In 43 patients aged 4-17 years with atopic BA and AR, the NM was examined using nasal video-endoscopy and (if indicated) computed tomography; the amount of periostin in the nasal secretion was determined by the enzyme immunoassay.

Results: Exacerbation of AR was accompanied by a statistically significant increase in the level of periostin in the nasal secretion: up to 0.84 [0.06; 48.79] ng/mg, whereas in remission, that was 0.13 [0.00; 0.36] ng/mg; p=0.04. This value increased progressively as the severity of AR increased from 0.16 [0.00; 0.36] ng/mg in the mild course to 0.20 [0.00; 9.03] ng/mg in AR of moderate severity, and to 10.70 [0.56; 769.20] ng/mg in most severe cases; p=0.048. Hypertrophy or polyposis of the nasal and/or paranasal mucosa was detected in 34.9% (15/43) of the examined patients. The concentration of periostin in the nasal secretion was lower in children without NM hypertrophy: 0.18 [0.001; 4.30] ng/mg vs 0.78 [0.13; 162.10] ng/mg in patients with NM hypertrophy; the differences were close to statistically significant: p=0.051. The level of nasal periostin depended on the clinical form of hypertrophy in the sinonasal mucosa, reaching 0.17 [0.00; 0.32] ng/mg in children with polyposis hyperplasia of NM and 21.6 [10.70; 1516.80] ng/mg - with hypertrophy of the NM in the medial surface of the concha; p=0.02.

Conclusion: Exacerbation and increased severity of AR in patients with atopic BA are accompanied by an increased level of periostin in the nasal secretion. This allows us to consider the level of nasal periostin as a biomarker of local allergic inflammation in the NM of patients with atopic BA combined with AR. Hypertrophic changes in the sinonasal mucosa are generally accompanied by an increased level of nasal periostin; specifically, this level significantly depends on the clinical form of mucous membrane hypertrophy and requires additional studies.

Keywords: allergic rhinitis; bronchial asthma; chronic rhinosinusitis with polyps; periostin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest. The authors have confirmed that there are no obvious and potential conflicts of interest that need to be reported.

Figures

Figure 1
Figure 1. Fragment of nasal video-endoscopy of patient S., 8 years old, diagnosed with bronchial asthma (atopic, persistent, under control), allergic rhinitis (persistent, severe) in the stage of exacerbation, and hypertrophy of the mucous membrane in the posterior parts of the inferior conchae
Hypertrophic changes in the mucous membrane of the posterior ends of the inferior conchae. Periostin level in the nasal secretion is 10.7 ng/mg
Figure 2
Figure 2. Fragment of nasal video-endoscopy of patient M., 9 years old, diagnosed with bronchial asthma (atopic, mild, intermittent) in remission, allergic rhinosinusitis (persistent), and polypoid rhinosinusitis
Polyposis associated hypertrophy of the mucous membrane that obturates the middle nasal passage on the left. Periostin level in the nasal secretion is 0.056 ng/mg
See this image and copyright information in PMC

References

    1. GINA. Global strategy for asthma management and prevention. 2019 URL: https://ginasthma.org/wp-content/up-loads/2019/06/GINA-2019-main-report-...
    1. Reddel H.K., FitzGerald J.M., Bateman E.D., Bacharier L.B., Becker A., Brusselle G., Buhl R., Cruz A.A., Fleming L., Inoue H., Ko F.W., Krishnan J.A., Levy M.L., Lin J., Pedersen S.E., Sheikh A., Yorgancioglu A., Boulet L.P. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046. doi: 10.1183/13993003.01046-2019. - DOI - PubMed
    1. Krasilnikova S.V., Eliseeva T.I., Popov K.S., Tush E.V., Khaletskaya O.V., Ovsyannikov D.Y., Balabolkin I.I., Shakhov A.V., Prahov A.V. Multimorbidity of upper respiratory tract pathology in children with bronchial asthma. Pediatria. Zhurnal im. G.N. Speranskogo. 2018;97(2):19–26.
    1. Krasilnikova S.V., Eliseeva Т.I., Shakhov А.V., Geppe N.A. Capabilities of nasal videoendoscopy in diagnostics of pharyngeal tonsil condition in children with bronchial asthma. Sovremennye tehnologii v medicine. 2016;8(3):126–136. doi: 10.17691/stm2016.8.3.15. - DOI
    1. Krasilnikova S.V., Tush Е.V., Babaev S.Yu., Khaletskaya A.I., Popov K.S., Novozhilov A.A., Abubakirov T.E., Eliseeva Т.I., Ignatov S.K., Shakhov A.V., Kubysheva N.I., Solovyev V.D. Endonasal infrared thermometry for the diagnosis of allergic inflammation of the nasal mucosa in patients with bronchial asthma. Sovremennye tehnologii v medicine. 2017;9(4):201–208. doi: 10.17691/stm2017.9.4.25. - DOI

Publication types